NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Auna (NYSE:AUNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Valuation & Earnings
This table compares NeuroOne Medical Technologies and Auna”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 3.51 | -$3.61 million | ($0.17) | -4.94 |
| Auna | $1.17 billion | 0.31 | $29.39 million | $0.71 | 6.80 |
Analyst Ratings
This is a summary of recent ratings for NeuroOne Medical Technologies and Auna, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 0 | 3 | 1 | 2.80 |
| Auna | 1 | 1 | 1 | 2 | 2.80 |
NeuroOne Medical Technologies currently has a consensus target price of $1.98, indicating a potential upside of 136.11%. Auna has a consensus target price of $7.30, indicating a potential upside of 51.30%. Given NeuroOne Medical Technologies’ higher probable upside, research analysts plainly believe NeuroOne Medical Technologies is more favorable than Auna.
Risk and Volatility
NeuroOne Medical Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Auna has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.
Profitability
This table compares NeuroOne Medical Technologies and Auna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -78.34% | -119.92% | -78.86% |
| Auna | 4.40% | 13.52% | 3.27% |
Insider & Institutional Ownership
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Auna beats NeuroOne Medical Technologies on 9 of the 14 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About Auna
Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
